BMS-986166 + phenytoin

BMS-986166 + phenytoin is a combination therapy that includes BMS-986166, a selective oral modulator of sphingosine-1-phosphate receptor 1 (S1P1R), and phenytoin, an established anticonvulsant and anti-epileptic drug. - **BMS-986166** is a prodrug that is phosphorylated to form the active metabolite BMS-986166-P. This metabolite acts as a *partial agonist* at S1P1R, resulting in immunomodulatory effects primarily through the sequestration of lymphocytes in lymphoid tissues. BMS-986166 has an improved cardiac safety profile compared to other S1P1R modulators and is under clinical development for various autoimmune diseases, including ulcerative colitis and atopic dermatitis[1][2][3][5][6][7][8]. - **Phenytoin** is a classic small-molecule sodium channel blocker used principally in epilepsy and some neuropathic conditions; it acts by stabilizing neuronal membranes and reducing excitability through antagonism of voltage-gated sodium channels. There is no established clinical rationale or reported evidence supporting the combined use of *BMS-986166 + phenytoin* as a structured co-formulation or combination product. No dedicated combination studies or branded products including these active ingredients together could be identified in clinical trials or regulatory sources.

Other names

BMS-986166 + phenytoin